The global hepatitis C treatment market was valued at US$ 25.02 Bn in
2016, and is expected to reach US$ 65.48 Bn by 2025, expanding at a CAGR
of 11.3% from 2017 to 2025.

For the purpose of the study hepatitis C treatment market is classified
on the basis of drug type such as interferons, ribavirin and direct
acting antivirals (DAA). Interferons and ribavirin are generally given
in combination to increase effectiveness of ribavirin against hepatitis
C.

It is estimated that DAA class will show highest market growth during
forecast period due to safety and effectiveness over previous treatment
approach. Newly approved medications such as zepatier (elbasvir
/gazoprevir), Epclusa (sofosbuvir /velpatasvir), Mavyret (glecaprevir
and pibrentasvir) and Vosevi (sofosbuvir, velpatasvir and voxilaprevir)
are expected to show significant market growth during forecast period.

It is studied that currently, North America is dominating the global
hepatitis C treatment market due to higher investment in drug
development, large number of affected population, higher cost of
medication, higher treatment awareness and upsurge in funding by the
government agencies in healthcare system are major factors that driving
the hepatitis C treatment market growth.

On the other hand, due to increasing healthcare awareness and developing
economic condition Asia Pacific would show significant hepatitis C
treatment market growth.